<DOC>
	<DOCNO>NCT02092766</DOCNO>
	<brief_summary>Delayed anaemia report European traveller malaria cured artesunate . Although death relate delayed anaemia report far , blood transfusion necessary affect patient . Recent observation suggest episode anaemia also occur endemic country . The aim trial ass incidence late onset anaemia treatment intravenous artesunate compare intravenous quinine , identify patient risk clarify cause delay anaemia .</brief_summary>
	<brief_title>Parenteral Artesunate Compared Quinine Cause Late Anaemia African Children With Malaria</brief_title>
	<detailed_description />
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Malaria</mesh_term>
	<mesh_term>Artesunate</mesh_term>
	<mesh_term>Artemisinins</mesh_term>
	<mesh_term>Quinine</mesh_term>
	<criteria>Age &gt; 6 month ≤ 14 year Acute uncomplicated P. falciparum malaria , confirm positive blood smear asexual form P. falciparum mixed nonfalciparum specie Asexual P. falciparum parasitaemia ≥ 100,000/uL ≤500,000/uL Haemoglobin ≥5.0 g/dL Parents/guardians agree hospitalize child length treatment ( 3 day ) bring patient plan followup visit day 7 , 14 , 21 , 28 , 35 , 42 Signed consent guardian/parents Body weight ≤ 5 kg Severe malaria sign severe malaria define WHO Guidelines 2013 History hypersensitivity contraindication quinine artesunate A clear history adequate antimalarial treatment precede 24 hour drug expect effective Presence intercurrent illness condition judgement investigator would place subject undue risk interfere patient treatment result study Participation another clinical trial</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>14 Years</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>malaria</keyword>
	<keyword>anaemia</keyword>
	<keyword>artesunate</keyword>
</DOC>